2024
Characterization of time toxicity in older patients with metastatic breast cancer
Atre S, Soulos P, Kuderer N, Gross C, Baum L, Dinan M, Lustberg M. Characterization of time toxicity in older patients with metastatic breast cancer. Breast Cancer Research And Treatment 2024, 207: 541-550. PMID: 38816556, DOI: 10.1007/s10549-024-07379-7.Peer-Reviewed Original ResearchMetastatic breast cancerBone-modifying agentsComorbid medical conditionsOlder patientsBreast cancerRetrospective cohort studySEER-Medicare databaseTreatment typeCancer treatment modalityTreatment modalitiesSEER-MedicareCohort studyUnadjusted analysisPatientsAge-related impactCancer treatmentComorbiditiesDay patientsCancerRadiotherapyOlder ageMedical conditionsToxicityTreatmentSociodemographic factorsIntegrating 4 Methods (In4M) to evaluate physical function in patients with cancer: Results of a comprehensive digital health study.
Thanarajasingam G, Dueck A, Bhatnagar V, Brown A, Cathcart-Rake E, Diamond M, Faust L, Fiero M, Huntington S, Jeffery M, Jones L, Paludo J, Power B, Ross J, Ruddy K, Schellhorn S, Tarver M, Wood W, Gross C, Kluetz P. Integrating 4 Methods (In4M) to evaluate physical function in patients with cancer: Results of a comprehensive digital health study. Journal Of Clinical Oncology 2024, 42: 1564-1564. DOI: 10.1200/jco.2024.42.16_suppl.1564.Peer-Reviewed Original ResearchPhysical functionPF measuresDaily stepsClinically meaningful change scoresAverage daily stepsEvaluate physical functionDigital health studiesMeasures of PFWearable dataHealth StudyWalk testWeekend daysCore outcomeChange scoresPerformance statusTreatment toleranceDetect changesPearson correlationECOG performance statusBreast cancerEvaluate feasibilityCancer trialsSignificant declineData collectionBaselineOutcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.
Tarantino P, Lee D, Foldi J, Soulos P, Gross C, Grinda T, Winer E, Lin N, Krop I, Tolaney S, Lustberg M, Sammons S. Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer. Journal Of Clinical Oncology 2024, 42: 1077-1077. DOI: 10.1200/jco.2024.42.16_suppl.1077.Peer-Reviewed Original ResearchReal-world progression-free survivalLines of therapyMetastatic breast cancerMedian real-world progression-free survivalT-DXdHER2+Overall survivalHER2-lowHER2- patientsBreast cancerHER2- metastatic breast cancerTreat metastatic breast cancerProgression-free survivalKaplan-Meier methodLines of treatmentDatabase of patientsRetrospective observational studyClinical trial settingHER2 casesIHC 0Trastuzumab deruxtecanHR statusHER2 statusTriple-negativeMedian ageFunctional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study
Sedrak M, Sun C, Bae M, Freedman R, Magnuson A, O’Connor T, Moy B, Wildes T, Klepin H, Chapman A, Tew W, Dotan E, Fenton M, Kim H, Katheria V, Muss H, Cohen H, Gross C, Ji J. Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study. Journal Of Cancer Survivorship 2024, 18: 1131-1143. PMID: 38678525, PMCID: PMC11324395, DOI: 10.1007/s11764-024-01594-3.Peer-Reviewed Original ResearchEarly-stage breast cancerPF-10 scorePF-10Physical functionNon-cancer controlsFunctional declineBC controlOlder breast cancer survivorsRAND 36-Item Short FormBreast cancerCohort of older adultsOlder womenBreast cancer survivorsImprove health outcomesPhysical function subscalePhysical function declineAccelerated functional declineBreast Cancer StudyCancer survivorsFunction subscaleHealth outcomesGroup of womenOlder adultsControl groupShort formIntegrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort study
Thanarajasingam G, Kluetz P, Bhatnagar V, Brown A, Cathcart-Rake E, Diamond M, Faust L, Fiero M, Huntington S, Jeffery M, Jones L, Noble B, Paludo J, Powers B, Ross J, Ritchie J, Ruddy K, Schellhorn S, Tarver M, Dueck A, Gross C. Integrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort study. BMJ Open 2024, 14: e074030. PMID: 38199641, PMCID: PMC10806877, DOI: 10.1136/bmjopen-2023-074030.Peer-Reviewed Original ResearchConceptsPhysical function assessmentPhysical functionFunctional assessmentEvaluation of physical functionElectronic health record dataEvaluate physical functionHealth record dataSpanish-speaking patientsDigital health technologiesBreast cancerProspective cohort studyClinician-reported outcomesCancer clinical trialsClinical decision-makingStudy questionnairePatient-centred evaluationHealth technologiesMeasure symptomsOncology practiceCohort studyRecord dataPatient's impressionMayo ClinicEnglish-speakingWearable sensors
2023
Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States.
Richman I, Long J, Soulos P, Wang S, Gross C. Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States. Annals Of Internal Medicine 2023, 176: 1172-1180. PMID: 37549389, PMCID: PMC10623662, DOI: 10.7326/m23-0133.Peer-Reviewed Original ResearchConceptsCumulative incidenceBreast cancerBreast cancer screeningUnscreened womenOlder womenCancer screeningBreast cancer-specific deathBreast cancer overdiagnosisService Medicare claimsRetrospective cohort studyCancer-specific deathBreast cancer deathsWomen 70 yearsHarms of overdiagnosisNational Cancer InstituteBreast cancer diagnosisCohort studyCancer overdiagnosisCancer deathSEER programMedicare claimsCancer InstituteOverdiagnosisGreater incidenceCancerRelative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.Peer-Reviewed Original ResearchConceptsLong-term survivorsCancer-specific mortalityColorectal cancerCancer cohortReceptor statusInitial diagnosisGleason scoreProstate cancerBreast cancerLong-term adult survivorsMedian cancer-specific survivalEnd Results cancer registryProstate-specific antigen levelRectal cancer cohortCancer-specific survivalStage III diseaseYear of diagnosisProgesterone receptor statusEstrogen receptor statusProportion of deathsSurvival time ratioEarly-stage cancerNononcologic outcomesIndex cancerLocalized diseaseFalls and hospitalization during chemotherapy in older women with early breast cancer.
Ji J, Sun C, Wildes T, Freedman R, Magnuson A, O'Connor T, Moy B, Klepin H, Chapman A, Tew W, Dotan E, Fenton M, Kim H, Bae M, Katheria V, Gross C, Muss H, Cohen H, Sedrak M. Falls and hospitalization during chemotherapy in older women with early breast cancer. Journal Of Clinical Oncology 2023, 41: 12035-12035. DOI: 10.1200/jco.2023.41.16_suppl.12035.Peer-Reviewed Original ResearchRisk of hospitalizationEarly breast cancerFall historyBreast cancerOlder adultsOlder womenStage II/III diseaseProspective multicenter studyMultivariable logistic regressionSelf-reported fall historyAdjuvant chemoCommon toxicitiesFebrile neutropeniaPrimary endpointPrimary prophylaxisGeriatric assessmentOlder patientsClinical factorsMedian ageAvoidable complicationsMulticenter studyClinical covariatesTreatment decisionsHospitalizationWomen's age
2022
Genetic testing in privately insured women with surgically treated breast cancer
Dinan M, Pitafi S, Greenup R, Long J, Gross C. Genetic testing in privately insured women with surgically treated breast cancer. Breast Cancer Research And Treatment 2022, 198: 177-181. PMID: 36542252, DOI: 10.1007/s10549-022-06829-4.Peer-Reviewed Original ResearchConceptsBreast cancerGenetic testingRoutine breast cancer careBRCA1/BRCA2 genetic testingHormone receptor statusBreast cancer careInvasive breast cancerBRCA2 genetic testingReceptor statusWomen 50Cancer careAge 45Family historyOlder womenInsurer databaseYoung womenCancerWomenCoverage policiesUnclear implicationsPatientsSurgeryPurposeRatesYearsPrevalence
2021
Building a Digital Health Risk Calculator for Older Women with Early-Stage Breast Cancer
Abujarad F, Wang S, Ulrich D, Mougalian S, Killelea B, Fraenkel L, Gross C, Evans S. Building a Digital Health Risk Calculator for Older Women with Early-Stage Breast Cancer. Lecture Notes In Computer Science 2021, 12780: 389-402. DOI: 10.1007/978-3-030-78224-5_27.Peer-Reviewed Original ResearchEarly-stage breast cancerOlder womenBreast cancerRadiation therapyTreatment therapiesEvidence-based treatment decisionsShared-decision modelRisk-benefit informationRisk calculatorRelative riskTreatment decisionsPatient healthDigital health toolsPatient comprehensionTherapyHealth toolsWomenCancerHealthPatientsCliniciansHow did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?
Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.Peer-Reviewed Original ResearchUse of NTNeoadjuvant therapyEarly pandemic periodBreast cancerNon-metastatic breast cancerPractice settingsEarly pandemicFlatiron Health databaseNeoadjuvant endocrine therapyTechnology-enabled abstractionSame period one yearSimilar clinicopathologic featuresLongitudinal electronic health recordsPeriod one yearElectronic health recordsTNBC subsetEndocrine therapyPatient ageTN patientsClinicopathologic featuresContemporary cohortClinical stageCancer clinicCancer managementHigh risk
2020
The association between Medicare’s next generation sequencing (NGS), national coverage decision (NCD), and NGS utilization.
Wong W, Sheinson D, Ogale S, Flores C, Gross C. The association between Medicare’s next generation sequencing (NGS), national coverage decision (NCD), and NGS utilization. Journal Of Clinical Oncology 2020, 38: 98-98. DOI: 10.1200/jco.2020.38.29_suppl.98.Peer-Reviewed Original ResearchMetastatic breast cancerMetastatic colorectal cancerAdvanced non-small cell lung cancerNational coverage decisionNGS testingUtilization trendsNext-generation sequencingNGS testsNon-small cell lung cancerCell lung cancerInterrupted time series analysisDe-identified databaseDiagnosis dateAdvanced melanomaPrimary cancerRetrospective studyColorectal cancerLung cancerInsurance typeCancer clinicMetastatic cancerBreast cancerUse of NGSTesting ratesCancer
2019
“Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer
Wang SY, Abujarad F, Chen T, Evans SB, Killelea BK, Mougalian SS, Fraenkel L, Gross C. “Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer. Journal Of Geriatric Oncology 2019, 11: 850-859. PMID: 31899199, PMCID: PMC7263974, DOI: 10.1016/j.jgo.2019.12.010.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerRisk calculatorLocal recurrenceBreast cancerOlder womenTumor characteristicsBreast cancer-specific outcomesReceipt of radiotherapyCancer-specific outcomesEarly breast cancerIndividual patient's riskBenefits of radiotherapyAdvisory CommitteeLife expectancyOnline risk calculatorLong-term survivalShared decision makingBenefit of RTOlder adult womenRadiotherapy statusCause mortalityOverall survivalRecurrence reductionFunctional statusPatient riskAbandonment trajectories of conventionally fractionated adjuvant radiotherapy in breast cancer care.
Xu X, Soulos P, Herrin J, Wang S, Pollack C, Evans S, Gross C, Yu J. Abandonment trajectories of conventionally fractionated adjuvant radiotherapy in breast cancer care. Journal Of Clinical Oncology 2019, 37: 531-531. DOI: 10.1200/jco.2019.37.15_suppl.531.Peer-Reviewed Original ResearchPhysician peer groupsBreast cancer careAdjuvant radiotherapyCancer careHigher useNational Medicare claimsPatient risk factorsDistinct trajectoriesYears of ageLow useDifferent baseline levelsRisk-adjusted ratesPatient cohortRisk factorsBreast cancerCost implicationsMedicare claimsBaseline levelsRadiotherapyMedicare perspectiveCFRTCurve analysisPhysiciansPatientsLatent growth curve analysis
2018
Persistent Use of Extended Fractionation Palliative Radiation Therapy for Medicare Beneficiaries with Metastatic Breast Cancer: 2011-2014
Yu J, Pollack C, Herrin J, Zhu W, Soulos P, Xu X, Gross C. Persistent Use of Extended Fractionation Palliative Radiation Therapy for Medicare Beneficiaries with Metastatic Breast Cancer: 2011-2014. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e425. DOI: 10.1016/j.ijrobp.2018.07.1241.Peer-Reviewed Original ResearchAdherence to Guidelines for Breast Surveillance in Breast Cancer Survivors.
Ruddy KJ, Sangaralingham L, Freedman RA, Mougalian S, Neuman H, Greenberg C, Jemal A, Duma N, Haddad TC, Lemaine V, Ghosh K, Hieken TJ, Hunt K, Vachon C, Gross C, Shah ND. Adherence to Guidelines for Breast Surveillance in Breast Cancer Survivors. Journal Of The National Comprehensive Cancer Network 2018, 16: 526-534. PMID: 29752327, DOI: 10.6004/jnccn.2018.7001.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsCancer survivorsBreast cancerDecreased likelihoodDefinitive breast cancer surgeryLikelihood of mammographySurvivorship care guidelinesCurative-intent treatmentProportion of patientsNonmetastatic breast cancerResidual breast tissueBreast cancer surgeryAdministrative claims dataBreast imagingBreast cancer treatmentMedicare Advantage beneficiariesBreast surveillanceInsured cohortPatient characteristicsAnnual mammographyCancer surgeryCare guidelinesBreast surgeryHealthcare useBlack race
2017
Mammography use in breast cancer survivors: An administrative claims study.
Ruddy K, Sangaralingham L, Neuman H, Greenberg C, Freedman R, Jemal A, Mougalian S, Hunt K, Haddad T, Lemaine V, Ghosh K, Hieken T, Vachon C, Gross C, Shah N. Mammography use in breast cancer survivors: An administrative claims study. Journal Of Clinical Oncology 2017, 35: 6531-6531. DOI: 10.1200/jco.2017.35.15_suppl.6531.Peer-Reviewed Original ResearchBreast cancer survivorsResidual breast tissueCancer survivorsMammography useBreast surgeryBreast cancerEarly-stage breast cancerMetastatic breast cancer diagnosisBreast tissueAnnual surveillance mammographyDefinitive breast surgeryOperable breast cancerCancer diagnosisCommercial insurance databaseProportion of patientsYear of diagnosisMultivariable logistic regressionStage breast cancerAdministrative claims dataYears of ageFirst yearBreast cancer diagnosisInsured cohortUnderwent mammographyRecurrent diseaseDuration of neoadjuvant endocrine therapy and breast cancer outcomes.
Mougalian S, Soulos P, Lannin D, Pusztai L, Gross C, Killelea B. Duration of neoadjuvant endocrine therapy and breast cancer outcomes. Journal Of Clinical Oncology 2017, 35: e12129-e12129. DOI: 10.1200/jco.2017.35.15_suppl.e12129.Peer-Reviewed Original ResearchNeoadjuvant endocrine therapyEndocrine therapyClinical stagePathologic stageNational Cancer Data BasePR-positive breast cancerHigher nodal stageNetwork cancer programsAdjuvant endocrine therapyMultiple comorbid conditionsBreast cancer outcomesPopulation of patientsType of surgeryPositive breast cancerSimilar response ratesNeoadjuvant chemotherapyUnderwent surgeryNodal stageComorbid conditionsCancer outcomesLarge tumorsCancer programsBreast cancerOlder womenPatientsThe Impact of Social Contagion on Physician Adoption of Advanced Imaging Tests in Breast Cancer
Pollack CE, Soulos PR, Herrin J, Xu X, Christakis NA, Forman HP, Yu JB, Killelea BK, Wang SY, Gross CP. The Impact of Social Contagion on Physician Adoption of Advanced Imaging Tests in Breast Cancer. Journal Of The National Cancer Institute 2017, 109: djw330. PMID: 28376191, PMCID: PMC6059114, DOI: 10.1093/jnci/djw330.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingBaseline usePositron emission tomography scanEnd Results-MedicareEmission tomography scanBreast cancer practiceImaging modalitiesAdvanced imaging testsHierarchical logistic regression modelsLogistic regression modelsPatient characteristicsUnproven benefitCancer practiceMRI/PETTomography scanBreast cancerMRI useImaging testsClinical practicePET useResonance imagingPET imagingPhysician peersPhysician adoptionBaseline periodRacial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
Davis BA, Aminawung JA, Abu-Khalaf MM, Evans SB, Su K, Mehta R, Wang SY, Gross CP. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study. Journal Of The National Comprehensive Cancer Network 2017, 15: 346-354. PMID: 28275035, DOI: 10.6004/jnccn.2017.0034.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsConnecticutFemaleGene Expression ProfilingGenetic TestingHealth Services AccessibilityHealthcare DisparitiesHumansLymphatic MetastasisMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioPatient Outcome AssessmentPopulation SurveillanceRegistriesRetrospective StudiesSocioeconomic FactorsYoung AdultConceptsPopulation-based studyOncotype DXODX testingBreast cancerHispanic womenHormone receptor-positive breast cancerReceptor-positive breast cancerRetrospective population-based studyWhite womenRacial disparitiesGEP test resultsBreast cancer careBreast cancer outcomesStudy inclusion criteriaGene expression profiling testsMore white womenClinical characteristicsTest receiptCancer outcomesCancer careInclusion criteriaLogistic analysisEthnic disparitiesStatewide populationWomen